Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
A <i>liaF</i> Codon Deletion Abolishes Daptomycin Bactericidal Activity against Vancomycin-Resistant <i>Enterococcus faecalis</i>
| Indexado |
|
||||
| DOI | 10.1128/AAC.00021-13 | ||||
| Año | 2013 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
The genetic bases for antibiotic tolerance are obscure. Daptomycin (DAP) is a lipopeptide antibiotic with bactericidal activity against enterococci. Using time-kill assays, we provide evidence for the first time that a deletion of isoleucine in position 177 of LiaF, a member of the three-component regulatory system LiaFSR involved in the cell envelope response to antimicrobials, is directly responsible for a DAP-tolerant phenotype and is likely to negatively affect response to DAP therapy.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | MUNITA-SEPULVEDA, JOSE MANUEL | Hombre |
Univ Texas Med Sch Houston - Estados Unidos
Universidad del Desarrollo - Chile University of Texas Medical School at Houston - Estados Unidos Clínica Alemana - Chile |
| 2 | Tran, Truc T. | Mujer |
Univ Texas Med Sch Houston - Estados Unidos
UNIV HOUSTON - Estados Unidos University of Texas Medical School at Houston - Estados Unidos University of Houston - Estados Unidos |
| 3 | Diaz, Lorena | Mujer |
Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Universidad El Bosque - Colombia |
| 4 | Panesso, Diana | Mujer |
Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Universidad El Bosque - Colombia |
| 5 | Reyes, Jinnethe | - |
Univ Texas Med Sch Houston - Estados Unidos
Univ El Bosque - Colombia University of Texas Medical School at Houston - Estados Unidos Universidad El Bosque - Colombia |
| 6 | Murray, Barbara | Mujer |
Ctr Study Emerging & Reemerging Pathogens - Estados Unidos
Univ Texas Med Sch Houston - Estados Unidos Center for the Study of Emerging and Reemerging Pathogens - Estados Unidos University of Texas Medical School at Houston - Estados Unidos |
| 7 | Arias, Cesar A. | Hombre |
Univ Texas Med Sch Houston - Estados Unidos
Ctr Study Emerging & Reemerging Pathogens - Estados Unidos Univ El Bosque - Colombia |
| 7 | Ariasa, Cesar A. | Hombre |
University of Texas Medical School at Houston - Estados Unidos
Center for the Study of Emerging and Reemerging Pathogens - Estados Unidos Universidad El Bosque - Colombia Univ Texas Med Sch Houston - Estados Unidos Ctr Study Emerging & Reemerging Pathogens - Estados Unidos Univ El Bosque - Colombia |
| Fuente |
|---|
| National Institute of Allergy and Infectious Diseases |
| Johnson Johnson |
| Pfizer, Inc. |
| Astellas |
| Cubist |
| B.E.M. |
| NIH from the National Institute of Allergy and Infectious Diseases (NIAID) |
| Forest Pharmaceuticals and Theravance |
| Palumed |
| Intercell |
| Agradecimiento |
|---|
| This work was supported by NIH grants R00 AI72961 and R01 AI093749 to C.A.A. from the National Institute of Allergy and Infectious Diseases (NIAID). B.E.M. was supported in part by NIH R01 AI047923. C.A.A. has received lecture fees, research support, and consulting fees from Pfizer, Inc., and Cubist and research support from Forest Pharmaceuticals and Theravance and has served as speaker for Novartis. B.E.M. received grant support from Johnson & Johnson, Astellas, Palumed, Intercell, and Cubist and has served as consultant for Astellas (Theravance), Cubist, Targanta Therapeutics (now owned by The Medicines Company), Pfizer, The Medicines Company, Rib-X, and Durata Therapeutics. J.M.M, T.T.T., L.D., D.P., and J.R. declare that we have no conflicts of interest. |
